1917

It is founded
Istituto Gentili

1917-97

Marketing
of products under the
Istituto Gentili brand

2009

The Mediolanum
pharmaceutical group
takes over the Istituto Gentili
from Merck Sharp & Dohme
Italia group

2017

AcquisitionTherabel
by the Mediolanum Pharmaceutical group

2017

With the deal with Novartis Farma S.p.A
the new reality of Istituto Gentili
is born,
entirely focused on
oncology

2018

The acquisition of
Teva's Italia Srl OncoCare products

further strengthens
the Portfolio of Istituto Gentili's products

2020

Acquisition of 3 products
that allowed to expand the
company's response
to the fight
against breast cancer

2021

Acquisition of one product dedicated to supportive
therapies for cancer patients.

2021

The deal with Norgine Italia has consolidated the company's commitment to support the cancer patient at 360°

2022

The consolidated deal with Novartis Farma S.p.A. strengthens the company's commitment in oncology (kidney cancer and soft tissue sarcomas)